8970 related articles for article (PubMed ID: 17310834)
1. Focus on Fotemustine.
De Rossi A; Rossi L; Laudisi A; Sini V; Toppo L; Marchesi F; Tortorelli G; Leti M; Turriziani M; Aquino A; Bonmassar E; De Vecchis L; Torino F
J Exp Clin Cancer Res; 2006 Dec; 25(4):461-8. PubMed ID: 17310834
[TBL] [Abstract][Full Text] [Related]
2. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
3. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT.
Christmann M; Pick M; Lage H; Schadendorf D; Kaina B
Int J Cancer; 2001 Apr; 92(1):123-9. PubMed ID: 11279615
[TBL] [Abstract][Full Text] [Related]
4. [Study of the clinical pharmacokinetics of fotemustine in various tumor indications].
Lokiec F; Beerblock K; Deloffre P; Lucas C; Bizzari JP
Bull Cancer; 1989; 76(10):1063-9. PubMed ID: 2635634
[TBL] [Abstract][Full Text] [Related]
5. Nitrosoureas: a review of experimental antitumor activity.
Schabel FM
Cancer Treat Rep; 1976 Jun; 60(6):665-98. PubMed ID: 782694
[TBL] [Abstract][Full Text] [Related]
6. Fotemustine for the treatment of melanoma.
Quéreux G; Dréno B
Expert Opin Pharmacother; 2011 Dec; 12(18):2891-904. PubMed ID: 22077794
[TBL] [Abstract][Full Text] [Related]
7. Fotemustine and recurrent glioblastoma: possible new opportunities for an old drug.
Addeo R; De Santi MS; Del Prete S; Caraglia M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):863-6. PubMed ID: 19639315
[No Abstract] [Full Text] [Related]
8. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
9. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
10. [Contribution of a new nitrosourea compound: fotemustine].
Boaziz C
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):964-8. PubMed ID: 1338920
[TBL] [Abstract][Full Text] [Related]
11. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
[TBL] [Abstract][Full Text] [Related]
13. [New toxicity of fotemustine: diffuse interstitial lung disease].
Bertrand M; Wémeau-Stervinou L; Gauthier S; Auffret M; Mortier L
Ann Dermatol Venereol; 2012 Apr; 139(4):277-81. PubMed ID: 22482481
[TBL] [Abstract][Full Text] [Related]
14. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.
Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V
Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
[TBL] [Abstract][Full Text] [Related]
17. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of fotemustine and BCNU in plasma, liver and tumor tissue of rats bearing two lines of Walker 256 carcinoma.
Guaitani A; Corada M; Lucas C; Lemoine A; Garattini S; Bartosek I
Cancer Chemother Pharmacol; 1991; 28(4):293-7. PubMed ID: 1879046
[TBL] [Abstract][Full Text] [Related]
19. [Brain metastases of malignant melanomas].
Boaziz C; Breau JL; Morere JF; Israël L
Bull Cancer; 1991; 78(4):347-53. PubMed ID: 1859902
[TBL] [Abstract][Full Text] [Related]
20. Phase I-II and pharmacokinetic study of a new fotemustine schedule in advanced non-small cell lung cancer.
Le Cesne A; Chabot G; Bérille J; Lucas C; Baud M; Gouyette A; Marty M; Le Chevalier T
Lung Cancer; 1995 Aug; 13(1):69-78. PubMed ID: 8528641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
